🏠💡 Breaking barriers in understanding homelessness and mental health! New research reveals staggering connections – up to 75% of homeless individuals face underlying mental health conditions. Learn more: bit.ly/444S7yY

Such amazing teamwork - honored to be a co-author! As for #pharmacogenetics and #TDM, the main conclusion is a shout-out for action before 'giving up' on medications, before suspecting 'treatment resistance' (or: difficult to treat #depression), and before seeking alternative

During #MentalHealthWeek, we recognize the vital role of support services like Hope + Me in navigating mood disorders. Their free programs offer evidence-based peer support & promote self-care on the path to recovery. Learn more: hopeandme.org #CompassionConnects

What are the changes in recommendations for MDD augmentation (add-on treatments) in the new 2023 Canadian Network for Mood and Anxiety Treatments update? Lets start with comparing the two tables side by side (2016 versus 2023) Full 2023 guidelines here (open access): pubmed.ncbi.nlm.nih.gov/38711351/ A thread 1/10

A model of a membrane called the blood–brain barrier could transform how scientists study drug delivery to the brain, as well as diseases of the brain’s vascular network go.nature.com/3ULhSjx

Honored to be part of this large-scale analyses paper, now published ('hot of the press') in molecularpsychiatry via collaboration with Tempus : "Pharmacogenomic Insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and

Review summarizes current evidence regarding the diagnosis and treatment of depression in adults. ja.ma/4ehXEHe

Depression-anxiety coupling strength predicts relapse in major depressive disorder. pubmed.ncbi.nlm.nih.gov/38866253/

New The CAN-BIND Program data hot off the press! Authors found that CYP2C19 rs4244285 was associated with weight gain in IM and NMs but not PMs, suggesting a biomarker and functional target for understanding antidepressant weight gain. thieme-connect.de/products/ejour…

We are excited to announce that Dr. Sakina Rizvi has been appointed as the new Chair of the ASR Suicide & Depression Studies Program. As Chair, Dr. Rizvi will develop and lead research to prevent, diagnose, and treat patients with depression and suicidality. Congratulations! 🎉

Did you know that The CAN-BIND Program, one of OBI’s Integrated Discovery Programs, is dedicated to transforming the treatment of #depression? 🔬 Focusing on addressing the need for accurate and rapid depression treatment by identifying objective measures known as biomarkers, The CAN-BIND Program paves

Are you or someone you know experiencing a major depressive episode? The CAN-BIND Program is recruiting for the Optimum-D Study, aiming to predict treatment responses using biomarkers for more personalized #depression care. 🔬 Hear more from Dr. Rudolf Uher of Dalhousie University and Dr.

Exciting news for workplace mental health advocates! The 5th Annual Workplace Mental Health Conference at the University of Michigan is on August 7th! This year’s event, "A Comprehensive Approach to Worker Well-Being," will spotlight employee mental health and supportive workplace culture.

We're proud to support the launch of the Psychedelics Health and Science Collaborative (PHSC), a groundbreaking Ontario-led initiative in mental health treatment! Congrats to our partners at Queen's University, Providence Care and The CAN-BIND Program for bringing this visionary centre to life.

Congratulations Dr. Jill Murphy on a well deserved and prestigious appointment and the opportunity to set an exciting research agenda! Canadian Network for Mood and Anxiety Treatments APEC Mental Health The CAN-BIND Program UBC Department of Psychiatry

Learn how #MentalHealth structural stigma manifests within our #Healthcare organisations & discover how you can help dismantle it with this FREE, quick-to-complete, micro eLearning course. Developed in partnership with the Mental Health Commission of Canada 👉 bit.ly/429aXTq HealthCareCAN

Alaina Jaster, PhD Joshua Rosenblat, MD, MSc, FRCPC at CAMH is a major Canadian lab. The CAN-BIND Program collaborator.

Raymond Lam Alaina Jaster, PhD Joshua Rosenblat, MD, MSc, FRCPC CAMH The CAN-BIND Program Josh and Ishrat Husain are running multiple trials in Toronto 👍🏻

Has there been much progress in treatment of BD and what does the future hold for potential exciting developments? Watch the Neurotorium video that provides a brief summary. neurotorium.org/video/bipolar-…

A very intriguing study documenting the efficacy of open-label placebo in the treatment of chronic back pain no doubt, neurobiological mechanisms extend to other psychiatry disorders including depression jamanetwork.com/journals/jaman…